caffeic acid phenethyl ester has been researched along with ag 1879 in 1 studies
| Studies (caffeic acid phenethyl ester) | Trials (caffeic acid phenethyl ester) | Recent Studies (post-2010) (caffeic acid phenethyl ester) | Studies (ag 1879) | Trials (ag 1879) | Recent Studies (post-2010) (ag 1879) |
|---|---|---|---|---|---|
| 840 | 1 | 469 | 575 | 0 | 215 |
| Protein | Taxonomy | caffeic acid phenethyl ester (IC50) | ag 1879 (IC50) |
|---|---|---|---|
| Chain A, Lck Kinase | Homo sapiens (human) | 0.02 | |
| Chain A, Tyrosine-protein kinase Lyn | Mus musculus (house mouse) | 0.009 | |
| Chain A, Tyrosine-protein kinase Lyn | Mus musculus (house mouse) | 0.009 | |
| Receptor-interacting serine/threonine-protein kinase 2 | Homo sapiens (human) | 0.019 | |
| Proto-oncogene tyrosine-protein kinase Src | Gallus gallus (chicken) | 0.036 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.48 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 0.004 | |
| Proto-oncogene tyrosine-protein kinase LCK | Mus musculus (house mouse) | 0.031 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 0.0052 | |
| Tyrosine-protein kinase Lyn | Homo sapiens (human) | 0.0005 | |
| Tyrosine-protein kinase HCK | Homo sapiens (human) | 0.005 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 1.1814 | |
| Tyrosine-protein kinase CSK | Homo sapiens (human) | 0.5 | |
| Casein kinase I isoform delta | Homo sapiens (human) | 0.041 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 4.23 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, MR; Maruta, H | 1 |
1 review(s) available for caffeic acid phenethyl ester and ag 1879
| Article | Year |
|---|---|
From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy.
Topics: Animals; Antineoplastic Agents; Click Chemistry; Drug Discovery; Humans; Longevity; Neoplasms; p21-Activated Kinases; Protein Kinase Inhibitors | 2017 |